Sage Therapeutics, Inc. (NASDAQ:SAGE – Free Report) – Stock analysts at HC Wainwright reduced their Q3 2023 earnings per share estimates for Sage Therapeutics in a report issued on Tuesday, August 8th. HC Wainwright analyst D. Tsao now expects that the biopharmaceutical company will earn ($2.49) per share for the quarter, down from their previous […]
Sage Therapeutics, Inc. (NASDAQ:SAGE – Free Report) – Equities researchers at Leerink Partnrs reduced their Q3 2023 earnings estimates for shares of Sage Therapeutics in a research report issued on Monday, August 7th. Leerink Partnrs analyst M. Goodman now forecasts that the biopharmaceutical company will post earnings of ($2.59) per share for the quarter, down […]
Sage Therapeutics, Inc. (NASDAQ:SAGE – Free Report) – Research analysts at HC Wainwright dropped their Q3 2023 earnings estimates for shares of Sage Therapeutics in a research note issued to investors on Tuesday, August 8th. HC Wainwright analyst D. Tsao now forecasts that the biopharmaceutical company will earn ($2.49) per share for the quarter, down […]
Sage Therapeutics, Inc. (NASDAQ:SAGE – Free Report) – Equities researchers at Leerink Partnrs decreased their Q3 2023 earnings per share (EPS) estimates for shares of Sage Therapeutics in a research note issued to investors on Monday, August 7th. Leerink Partnrs analyst M. Goodman now anticipates that the biopharmaceutical company will earn ($2.59) per share for […]
Sage Therapeutics, Inc. (NASDAQ:SAGE – Free Report) – Investment analysts at HC Wainwright dropped their Q3 2023 earnings estimates for Sage Therapeutics in a report released on Tuesday, August 8th. HC Wainwright analyst D. Tsao now forecasts that the biopharmaceutical company will post earnings of ($2.49) per share for the quarter, down from their prior […]